Back to top
more

Myriad Genetics (MYGN)

(Delayed Data from NSDQ)

$23.39 USD

23.39
419,078

+0.06 (0.26%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $23.40 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Myriad (MYGN) Down 0.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Company News For Aug 23, 2018

    by Zacks Equity Research

    Companies In The News are: TGT,LOW,NAVG,HIG,MYGN

      Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q4

      by Zacks Equity Research

      Myriad Genetics (MYGN) witnesses strong performances from GeneSight, EndoPredict, Vectra DA and Prolaris tests in Q4.

        Myriad Genetics (MYGN) Surpasses Q4 Earnings and Revenue Estimates

        by Zacks Equity Research

        Myriad (MYGN) delivered earnings and revenue surprises of 15.15% and 2.63%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

          Will Medtronic (MDT) Q1 Earnings Show Overall Progress?

          by Zacks Equity Research

          In Q1, Medtronic (MDT) is expected to have sustained a steady market share across the core pacing, ICD and CRT product lines.

            Can Molecular Diagnostics Drive Myriad's (MYGN) Q4 Earnings?

            by Zacks Equity Research

            Myriad (MYGN) likely to deliver solid Q4 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.

              Will Myriad (MYGN) Beat Estimates Again in Its Next Earnings Report?

              by Zacks Equity Research

              Myriad (MYGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

                Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx

                by Zacks Equity Research

                The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.

                  Why is Myriad Genetics (MYGN) Up 18.6% Since Its Last Earnings Report?

                  by Zacks Equity Research

                  Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Sweta Jaiswal headshot

                    Morgan Stanley Calls Labs 'Safe Havens': Stocks to Watch

                    by Sweta Jaiswal

                    With Morgan Stanley calling clinical laboratory services market a safe haven, let's find out what's working in favor and against this burgeoning niche market.

                      Myriad Genetics' Planned Counsyl Buyout to Widen Portfolio

                      by Zacks Equity Research

                      Myriad Genetics (MYGN) plans to retain Counsyl as a wholly-owned subsidiary post the successful completion of the acquisition.

                        Myriad Genetics' Prolaris Expands on New Coverage Decisions

                        by Zacks Equity Research

                        This increased rate in commercial insurer coverage for Myriad Genetics' (MYGN) Prolaris comes close on the heels of the NCCN guidelines.

                          Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q3

                          by Zacks Equity Research

                          Myriad Genetics' (MYGN) Q3 revenues decline year over year. Strong demand for GeneSight, Vectra DA and Prolaris tests was encouraging.

                            Can Molecular Diagnostics Drive Myriad's (MYGN) Q3 Earnings?

                            by Zacks Equity Research

                            Myriad Genetics (MYGN) likely to deliver solid Q3 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.

                              Here's Why You Should Invest in Integer Holdings Right Now

                              by Zacks Equity Research

                              Integer Holdings' (ITGR) unswerving focus on customer relationship, cost reduction and burgeoning financial performance are key catalysts.

                                Intuitive Surgical (ISRG) Beats on Q1 Earnings & Revenues

                                by Zacks Equity Research

                                Intuitive Surgical's (ISRG) da Vinci platform drives growth in Q1, international sales rise.

                                  Here's Why You Should Hold on to Cerner (CERN) Stock for Now

                                  by Zacks Equity Research

                                  Cerner (CERN) gains ground on solid EHR platform, stiff competition raises concern.

                                    Can MedSurg Business Aid Boston Scientific (BSX) Q1 Earnings?

                                    by Zacks Equity Research

                                    Boston Scientific's (BSX) MedSurg business is likely to deliver an encouraging show in Q1 on the back of a strong endoscopy, driven by biliary, hemostasis, EndoChoice and Symetis buyouts.

                                      Can LaunchPad Aid LabCorp's (LH) Covance Arm in Q1 Earnings?

                                      by Zacks Equity Research

                                      Labcorp's (LH) multi-year LaunchPad project holds enough promise for growth. Good news is that the company already grossed savings worth $20 million from the same in 2017.

                                        Can Neurotechnology & Spine Drive Stryker (SYK) Q1 Earnings?

                                        by Zacks Equity Research

                                        Stryker's (SYK) Neurotech business goes strong, VEXIM buyout likely to boost segment.

                                          Can S.E.T. Aid Zimmer (ZBH) Q1 Earnings Despite Supply Woes?

                                          by Zacks Equity Research

                                          Several FDA clearances within S.E.T since last November raise hope for Zimmer Biomet (ZBH) in Q1.

                                            What's in the Offing for Thermo Fisher (TMO) in Q1 Earnings?

                                            by Zacks Equity Research

                                            Thermo Fisher (TMO) benefits from its acquisition of FEI, consistently adding stimulus to its analytical instruments portfolio for over a year now.

                                              Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings?

                                              by Zacks Equity Research

                                              Abbott (ABT) poised to gain on continued growth in Medical devices business in Q1.

                                                Can Solid Overall Growth Drive Illumina's (ILMN) Q1 Earnings?

                                                by Zacks Equity Research

                                                Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other segments in Q1.

                                                  WATCHMAN to Aid Boston Scientific (BSX) Q1 Earnings Amid Woes

                                                  by Zacks Equity Research

                                                  The WATCHMAN platform is expected to experience a strong quarter on consistent global momentum as Boston Scientific's (BSX) multiple market development efforts continue to push for growth.